{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T06:00:09Z","timestamp":1790402409924,"version":"4.1.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T00:00:00Z","timestamp":1784332800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T00:00:00Z","timestamp":1784332800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["No. 21H03092"],"award-info":[{"award-number":["No. 21H03092"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Jpn J Ophthalmol"],"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>To investigate the association of hyperreflective foci (HRFs) with disease activity in treatment-na\u00efve neovascular age-related macular degeneration (nAMD) and to compare the effects of anti-vascular endothelial growth factor (VEGF) therapy versus dual VEGF-A\/angiopoietin-2 (Ang-2) inhibition on HRFs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Study design<\/jats:title>\n                    <jats:p>Retrospective, single-center, interventional study<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This study included 72 eyes with treatment-na\u00efve nAMD. Thirty-two consecutive eyes received aflibercept 2mg and 40 consecutive eyes received faricimab, each undergoing three monthly loading injections. HRF presence and area, central retinal thickness (CRT), best-corrected visual acuity (BCVA), and associated parameters were evaluated at baseline and after loading. HRFs were quantified using binarized spectral-domain optical coherence tomography (SD-OCT) images with automated assistance.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>At baseline, 45 eyes (62.5%) exhibited HRFs, all in the outer retina, with 10 eyes (13.9%) also showing inner retinal HRFs. Outer HRF area positively correlated with CRT and the maximum height of serous retinal detachment (SRD), while inner HRFs were associated with intraretinal fluid. Both treatments significantly improved BCVA and CRT. HRF presence and area decreased after treatment, primarily in the outer retina. After adjustment for baseline HRF area and clinical parameters, faricimab achieved a more substantial reduction in total, outer, and inner HRF areas than aflibercept.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>HRFs correlated with layer-specific exudative change. Faricimab resulted in a more pronounced reduction in HRFs than aflibercept despite comparable anatomical improvements, suggesting superior control of inflammation-related retinal changes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s10384-026-01392-7","type":"journal-article","created":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T02:40:57Z","timestamp":1784342457000},"page":"1165-1173","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Effects of vascular endothelial growth factor and angiopoietin-2 inhibitions on intraretinal hyperreflective foci in neovascular age-related macular degeneration"],"prefix":"10.1007","volume":"70","author":[{"given":"Yuta","family":"Nakanishi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Akada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryosuke","family":"Tamiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Midori","family":"Ideyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Kogo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ai","family":"Ichioka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akinari","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoko","family":"Ueda-Arakawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Tamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manabu","family":"Miyata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayako","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ai","family":"Kido","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Muraoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Miyake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sotaro","family":"Ooto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akitaka","family":"Tsujikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5248-5762","authenticated-orcid":false,"given":"Masayuki","family":"Hata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,18]]},"reference":[{"key":"1392_CR1","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1016\/S0140-6736(18)31550-2","volume":"392","author":"P Mitchell","year":"2018","unstructured":"Mitchell P, Liew G, Gopinath B, Wong TY. Age-related macular degeneration. Lancet. 2018;392:1147\u201359.","journal-title":"Lancet"},{"key":"1392_CR2","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.1016\/j.ophtha.2012.09.006","volume":"119","author":"JS Heier","year":"2012","unstructured":"Heier JS, Brown DM, Chong V, Korobelnik JF, Kaiser PK, Nguyen QD, et al. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology. 2012;119:2537\u201348.","journal-title":"Ophthalmology"},{"key":"1392_CR3","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1136\/bjophthalmol-2013-303513","volume":"97","author":"I Krebs","year":"2013","unstructured":"Krebs I, Glittenberg C, Ansari-Shahrezaei S, Hagen S, Steiner I, Binder S. Non-responders to treatment with antagonists of vascular endothelial growth factor in age-related macular degeneration. Br J Ophthalmol. 2013;97:1443\u20136.","journal-title":"Br J Ophthalmol"},{"key":"1392_CR4","doi-asserted-by":"publisher","first-page":"2292","DOI":"10.1016\/j.ophtha.2013.03.046","volume":"120","author":"S Rofagha","year":"2013","unstructured":"Rofagha S, Bhisitkul RB, Boyer DS, Sadda SR, Zhang K, Group S-US. Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON. Ophthalmology. 2013;120:2292\u20139.","journal-title":"Ophthalmology"},{"key":"1392_CR5","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.ajo.2023.03.033","volume":"252","author":"F Romano","year":"2023","unstructured":"Romano F, Cozzi E, Airaldi M, Nassisi M, Viola F, Aretti A, et al. Ten-year incidence of fibrosis and risk factors for its development in neovascular age-related macular degeneration. Am J Ophthalmol. 2023;252:170\u201381.","journal-title":"Am J Ophthalmol"},{"key":"1392_CR6","doi-asserted-by":"crossref","unstructured":"Regula JT, Lundh von Leithner P, Foxton R, Barathi VA, Cheung CM, Bo Tun SB, et al. Targeting key angiogenic pathways with a bispecific CrossMAb optimized for neovascular eye diseases. EMBO Mol Med. 2016;8:1265\u201388.","DOI":"10.15252\/emmm.201505889"},{"key":"1392_CR7","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1016\/S0140-6736(22)00010-1","volume":"399","author":"JS Heier","year":"2022","unstructured":"Heier JS, Khanani AM, Quezada Ruiz C, Basu K, Ferrone PJ, Brittain C, et al. Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials. Lancet. 2022;399:729\u201340.","journal-title":"Lancet"},{"key":"1392_CR8","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1136\/bjophthalmol-2011-300654","volume":"96","author":"MW Stewart","year":"2012","unstructured":"Stewart MW. Aflibercept (VEGF Trap-eye): the newest anti-VEGF drug. Br J Ophthalmol. 2012;96:1157\u20138.","journal-title":"Br J Ophthalmol"},{"key":"1392_CR9","doi-asserted-by":"publisher","first-page":"21128","DOI":"10.1038\/s41598-023-48190-6","volume":"13","author":"R Tamiya","year":"2023","unstructured":"Tamiya R, Hata M, Tanaka A, Tsuchikawa M, Ueda-Arakawa N, Tamura H, et al. Therapeutic effects of faricimab on aflibercept-refractory age-related macular degeneration. Sci Rep. 2023;13:21128.","journal-title":"Sci Rep"},{"key":"1392_CR10","doi-asserted-by":"publisher","first-page":"4487","DOI":"10.1007\/s00018-021-03796-9","volume":"78","author":"A Armento","year":"2021","unstructured":"Armento A, Ueffing M, Clark SJ. The complement system in age-related macular degeneration. Cell Mol Life Sci. 2021;78:4487\u2013505.","journal-title":"Cell Mol Life Sci"},{"key":"1392_CR11","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1126\/science.abj8894","volume":"379","author":"M Hata","year":"2023","unstructured":"Hata M, Andriessen E, Hata M, Diaz-Marin R, Fournier F, Crespo-Garcia S, et al. Past history of obesity triggers persistent epigenetic changes in innate immunity and exacerbates neuroinflammation. Science. 2023;379:45\u201362.","journal-title":"Science"},{"key":"1392_CR12","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1007\/s10384-024-01153-4","volume":"69","author":"K Tanaka","year":"2025","unstructured":"Tanaka K, Omori T, Oguchi Y, Itagaki K, Kato Y, Honjo J, et al. HTRA1 and complement activation in neovascular age-related macular degeneration. Jpn J Ophthalmol. 2025;69:453\u20139.","journal-title":"Jpn J Ophthalmol"},{"key":"1392_CR13","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/s00281-008-0112-9","volume":"30","author":"M Patel","year":"2008","unstructured":"Patel M, Chan CC. Immunopathological aspects of age-related macular degeneration. Semin Immunopathol. 2008;30:97\u2013110.","journal-title":"Semin Immunopathol"},{"key":"1392_CR14","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1186\/s12974-020-02033-7","volume":"17","author":"K Little","year":"2020","unstructured":"Little K, Llorian-Salvador M, Tang M, Du X, Marry S, Chen M, et al. Macrophage to myofibroblast transition contributes to subretinal fibrosis secondary to neovascular age-related macular degeneration. J Neuroinflammation. 2020;17:355.","journal-title":"J Neuroinflammation"},{"key":"1392_CR15","doi-asserted-by":"publisher","first-page":"5958","DOI":"10.1167\/iovs.17-22725","volume":"58","author":"HS Hwang","year":"2017","unstructured":"Hwang HS, Chae JB, Kim JY, Kim DY. Association between hyperreflective dots on spectral-domain optical coherence tomography in macular edema and response to treatment. Investig Ophthalmol Vis Sci. 2017;58:5958\u201367.","journal-title":"Investig Ophthalmol Vis Sci"},{"key":"1392_CR16","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1167\/iovs.17-23042","volume":"59","author":"H Lee","year":"2018","unstructured":"Lee H, Jang H, Choi YA, Kim HC, Chung H. Association between soluble CD14 in the aqueous humor and hyperreflective foci on optical coherence tomography in patients with diabetic macular edema. Investig Ophthalmol Vis Sci. 2018;59:715\u201321.","journal-title":"Investig Ophthalmol Vis Sci"},{"key":"1392_CR17","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1007\/s00417-019-04546-1","volume":"258","author":"Y Hsia","year":"2020","unstructured":"Hsia Y, Yang CH, Hsieh YT, Yang CM, Ho TC, Lai TT. Hyperreflective foci in predicting the treatment outcome of antivascular endothelial growth factor in neovascular age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol. 2020;258:273\u201380.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"1392_CR18","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s12974-023-02699-9","volume":"20","author":"S Augustin","year":"2023","unstructured":"Augustin S, Lam M, Lavalette S, Verschueren A, Blond F, Forster V, et al. Melanophages give rise to hyperreflective foci in AMD, a disease-progression marker. J Neuroinflammation. 2023;20:28.","journal-title":"J Neuroinflammation"},{"key":"1392_CR19","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1007\/s00417-010-1461-3","volume":"249","author":"HK Kuo","year":"2011","unstructured":"Kuo HK, Kuo MT, Tiong IS, Wu PC, Chen YJ, Chen CH. Visual acuity as measured with Landolt C chart and Early Treatment of Diabetic Retinopathy Study (ETDRS) chart. Graefes Arch Clin Exp Ophthalmol. 2011;249:601\u20135.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"1392_CR20","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1016\/j.ophtha.2012.10.018","volume":"120","author":"JG Christenbury","year":"2013","unstructured":"Christenbury JG, Folgar FA, O\u2019Connell RV, Chiu SJ, Farsiu S, Toth CA. Progression of intermediate age-related macular degeneration with proliferation and inner retinal migration of hyperreflective foci. Ophthalmology. 2013;120:1038\u201345.","journal-title":"Ophthalmology"},{"key":"1392_CR21","doi-asserted-by":"publisher","first-page":"6448","DOI":"10.1167\/iovs.15-17338","volume":"56","author":"K Abri Aghdam","year":"2015","unstructured":"Abri Aghdam K, Pielen A, Framme C, Junker B. Correlation between hyperreflective foci and clinical outcomes in neovascular age-related macular degeneration after switching to aflibercept. Investig Ophthalmol Vis Sci. 2015;56:6448\u201355.","journal-title":"Investig Ophthalmol Vis Sci"},{"key":"1392_CR22","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1007\/BF00175988","volume":"232","author":"AG Bennett","year":"1994","unstructured":"Bennett AG, Rudnicka AR, Edgar DF. Improvements on Littmann\u2019s method of determining the size of retinal features by fundus photography. Graefes Arch Clin Exp Ophthalmol. 1994;232:361\u20137.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"1392_CR23","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1016\/j.ophtha.2008.12.039","volume":"116","author":"M Bolz","year":"2009","unstructured":"Bolz M, Schmidt-Erfurth U, Deak G, Mylonas G, Kriechbaum K, Scholda C. Optical coherence tomographic hyperreflective foci: a morphologic sign of lipid extravasation in diabetic macular edema. Ophthalmology. 2009;116:914\u201320.","journal-title":"Ophthalmology"},{"key":"1392_CR24","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1097\/IAE.0b013e318217ffc7","volume":"32","author":"K Ogino","year":"2012","unstructured":"Ogino K, Murakami T, Tsujikawa A, Miyamoto K, Sakamoto A, Ota M, et al. Characteristics of optical coherence tomographic hyperreflective foci in retinal vein occlusion. Retina. 2012;32:77\u201385.","journal-title":"Retina"},{"issue":"710\u20137","key":"1392_CR25","first-page":"7.e1","volume":"153","author":"A Uji","year":"2012","unstructured":"Uji A, Murakami T, Nishijima K, Akagi T, Horii T, Arakawa N, et al. Association between hyperreflective foci in the outer retina, status of photoreceptor layer, and visual acuity in diabetic macular edema. Am J Ophthalmol. 2012;153(710\u20137):7.e1.","journal-title":"Am J Ophthalmol"},{"key":"1392_CR26","first-page":"605","volume":"10","author":"B Mo","year":"2017","unstructured":"Mo B, Zhou HY, Jiao X, Zhang F. Evaluation of hyperreflective foci as a prognostic factor of visual outcome in retinal vein occlusion. Int J Ophthalmol. 2017;10:605\u201312.","journal-title":"Int J Ophthalmol"},{"key":"1392_CR27","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1016\/S0140-6736(22)00018-6","volume":"399","author":"CC Wykoff","year":"2022","unstructured":"Wykoff CC, Abreu F, Adamis AP, Basu K, Eichenbaum DA, Haskova Z, et al. Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials. Lancet. 2022;399:741\u201355.","journal-title":"Lancet"},{"key":"1392_CR28","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1016\/j.ophtha.2024.01.029","volume":"131","author":"R Tadayoni","year":"2024","unstructured":"Tadayoni R, Paris LP, Danzig CJ, Abreu F, Khanani AM, Brittain C, et al. Efficacy and Safety of Faricimab for Macular Edema due to Retinal Vein Occlusion: 24-Week Results from the BALATON and COMINO Trials. Ophthalmology. 2024;131:950\u201360.","journal-title":"Ophthalmology"},{"key":"1392_CR29","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.201810204","volume":"11","author":"RH Foxton","year":"2019","unstructured":"Foxton RH, Uhles S, Gr\u00fcner S, Revelant F, Ullmer C. Efficacy of simultaneous VEGF-A\/ANG-2 neutralization in suppressing spontaneous choroidal neovascularization. EMBO Mol Med. 2019;11:e10204.","journal-title":"EMBO Mol Med"},{"key":"1392_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.xops.2025.100798","volume":"5","author":"U Chakravarthy","year":"2025","unstructured":"Chakravarthy U, Chaudhary V, Sadda SR, Tan CS, Vujosevic S, Fauser S, et al. Effect of faricimab versus aflibercept on hyperreflective foci in patients with diabetic macular edema from the YOSEMITE\/RHINE trials. Ophthalmol Sci. 2025;5:100798.","journal-title":"Ophthalmol Sci."},{"key":"1392_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.preteyeres.2021.100954","volume":"84","author":"A Uemura","year":"2021","unstructured":"Uemura A, Fruttiger M, D\u2019Amore PA, De Falco S, Joussen AM, Sennlaub F, et al. VEGFR1 signaling in retinal angiogenesis and microinflammation. Prog Retin Eye Res. 2021;84:100954.","journal-title":"Prog Retin Eye Res"},{"key":"1392_CR32","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.preteyeres.2017.06.002","volume":"61","author":"X Guillonneau","year":"2017","unstructured":"Guillonneau X, Eandi CM, Paques M, Sahel JA, Sapieha P, Sennlaub F. On phagocytes and macular degeneration. Prog Retin Eye Res. 2017;61:98\u2013128.","journal-title":"Prog Retin Eye Res"},{"key":"1392_CR33","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1007\/s00417-012-1928-5","volume":"250","author":"Y Akagi-Kurashige","year":"2012","unstructured":"Akagi-Kurashige Y, Tsujikawa A, Oishi A, Ooto S, Yamashiro K, Tamura H, et al. Relationship between retinal morphological findings and visual function in age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol. 2012;250:1129\u201336.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"1392_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.xops.2022.100125","volume":"2","author":"A Kido","year":"2022","unstructured":"Kido A, Miyake M, Tamura H, Hiragi S, Kimura T, Yoshida S, et al. Incidence and clinical practice of exudative age-related macular degeneration: a nationwide population-based cohort study. Ophthalmol Sci. 2022;2:100125.","journal-title":"Ophthalmol Sci."},{"key":"1392_CR35","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1016\/j.ophtha.2017.12.026","volume":"125","author":"SR Sadda","year":"2018","unstructured":"Sadda SR, Tuomi LL, Ding B, Fung AE, Hopkins JJ. Macular atrophy in the HARBOR study for neovascular age-related macular degeneration. Ophthalmology. 2018;125:878\u201386.","journal-title":"Ophthalmology"}],"container-title":["Japanese Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10384-026-01392-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10384-026-01392-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10384-026-01392-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T05:19:23Z","timestamp":1790399963000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10384-026-01392-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,18]]},"references-count":35,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["1392"],"URL":"https:\/\/doi.org\/10.1007\/s10384-026-01392-7","relation":{},"ISSN":["0021-5155","1613-2246"],"issn-type":[{"value":"0021-5155","type":"print"},{"value":"1613-2246","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,18]]},"assertion":[{"value":"18 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Y. Nakanishi, None; M. Akada, None; R. Tamiya, None; M. Ideyama, None; T. Kogo, None; A. Ichioka, None; A. Yamamoto, None; N. Ueda-Arakawa, Grants or contracts (Chugai, Alcon), Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events (Novartis, Chugai, Bayer, Rohto Nitten, Astellas); H. Tamura, Grants or contracts (Findex, Google), Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events (Bayer, Otsuka, Santen); M. Miyata, Grants or contracts (Alcon, Chugai, Santen, Bayer), Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events (Otsuka, Santen, Bayer, Senju, Kowa, Chugai); A. Takahashi, Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events (HOYA); A. Kido, Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events (Senju); Y. Muraoka, Grants or contracts (Alcon, Novartis, Bayer), Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events (Bayer, Novartis, Senju, Canon, Santen, AMO, HOYA, Johnson & Johnson); M. Miyake, Grants or contracts (Novartis, Daiichi Sankyo, Kaneka, Rohto, Bayer), Consulting fees (Janssen), Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events (Bayer, Kowa, Novartis, AMO, Santen, Senju, Johnson & Johnson, Chugai, Findex, Topcon), Patents planned, issued or pending (Kaneka, Findex); S. Ooto, Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events (Bayer, Novartis, Janssen, Kowa, AMO, Santen, Alcon, Senju, Chugai, HOYA); A. Tsujikawa, Grants or contracts (Canon, Findex, Santen, Sumitomo, Astellas, Otsuka, Senju, Alcon, Wakamoto, Chugai, HOYA, Rohto Nitten), Consulting fees (Senju, Boehringer Ingelheim, Chugai, Bayer, HOYA, Janssen, Sumitomo, Kyowa Kirin, Alcon, Santen, MSD), Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events (Santen, Senju, Novartis, Bayer, Chugai, Alcon, Otsuka, AMO, Wakamoto, Kowa, MSD, HOYA); M. Hata, Grants or contracts (Alcon, Bayer, Chugai), Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events (Senju, Chugai, Novartis, Bayer, Boehringer Ingelheim, Santen), Patents planned, issued or pending (Kyoto Drug Discovery and Development).","order":1,"name":"Ethics","label":"Conflicts of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}